Pegylated Interferon Alpha2A
Ascites Hepatic
Dormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Ascites Hepatic cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
NORMAL HUMAN SERUM ALBUMIN Anahita Rabiee MD MHS | Phase 4 | BB |
Empagliflozin Alexandria University | Phase 2/3 | BB |
Fresh Frozen Plasma Montefiore Medical Center | Phase 4 | B |
GLY-GLY-GLY-CYS-TYR-PHE-GLN-ASN-CYS-PRO-LYS-GLY-NH2 (4-9 DISULFIDE) Noorik Biopharmaceuticals AG | Phase 2 | B |
URODILATIN University of Aarhus | Phase 2 | CCC |
View all 11 →
Same molecule, other indications
Pegylated Interferon Alpha2A is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →